Veru Inc.
NCM: VERULive Quote
📈 ZcoreAI Score
Our AI model analyzes Veru Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get VERU Z-Score →About Veru Inc.
Healthcare
Biotechnology
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
📊 Fundamental Analysis
Veru Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -60.2%, which indicates that capital utilization is currently under pressure.
At a current price of $2.38, VERU currently trades near the bottom of its 52-week range (6%), indicating potential value or weakness (Range: $2.06 - $7.40).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$38.20M
Trailing P/E
--
Forward P/E
-1.98
Beta (5Y)
-1.34
52W High
$7.40
52W Low
$2.06
Avg Volume
79K
Day High
Day Low